As generic competition stutter sales of top oncology drugs, Roche secures speedy review for pair of experimental cancer offerings
As drug developers seek ways to expand therapeutic applications and overcome the hurdles seen with the first generation of antibody drug conjugates (ADCs), Roche …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
